AzTrials
AzTrials

Rheumatoid ArthritisPhase 1DekaJointNCT05622175

Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

A Phase 1 study testing F8IL10 in people with Rheumatoid Arthritis, run by Philogen S.p.A..

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a. administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
F8IL10
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
31 Mar 2023to 31 Dec 2026
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged ≥18 and ≤ 80 years.
  • Diagnosis of RA according to ACR/EULAR classification criteria (2010) with a disease duration exceeding 6 months.
  • Presence of at least an arthritis flare suitable for i.a. injection despite treatment with stable doses (for at least 3 months) of DMARDs (conventional, biologic and targeted synthetic) background therapy.
  • Stable regimens of NSAIDs and/or oral corticosteroid (≤ 10 mg/day; prednisone equivalent) for a period ≥ 2 weeks prior to screening.
  • All acute toxic effects of any prior therapy must have returned to classification "mild" according to CTCAE v.5.0 (published on November 27, 2017).
  • Sufficient hematologic, liver and renal function:
Show all 19Show fewer
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥100 x109/L, haemoglobin (Hb) ≥ 10.0 g/dL.
  • Alkaline phosphatase (AP), alanine aminotransferase (ALT) and or aspartate aminotransferase (AST) ≤ 3 x upper limit of normal range (ULN), and total bilirubin ≤ 2.0 mg/dl (34.2 µmol/L).
  • Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 50 mL/min.
  • Documented negative TB test (e.g. Quantiferon or equivalent) and Chest X-ray. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active TB by the study physician.
  • Documented negative test for HIV-HBV-HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no ongoing infection are eligible. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active infections by the study physician.
  • Sexually active male or female patients of childbearing potential are eligible providing that:
  • Female:
  • Women of childbearing potential (WOCBP) have a negative pregnancy test performed within 14 days prior to treatment start.
  • WOCBP agree to use, from the screening to 6 months following the last study drug administration, effective method of birth control as applicable per local law that both results in a Pearl index < 1 and considered highly effective as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the "Clinical Trial Facilitation Group" (e.g. combined estrogen and progestogen containing hormonal contraception, progestogen-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, vasectomized partner, total sexual abstinence or bilateral tubal occlusion).
  • Male:
  • Agree to use two acceptable methods of contraception (e.g. condom with spermicidal gel) from the screening to 6 months following the last study drug administration. Females of childbearing potential that are partners of male study participants must observe the same birth control indications that apply to female participants.
  • Signed and dated Ethics Committee-approved informed consent form indicating that the patient has been informed of all pertinent aspects of the study.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Who cannot join

  • Patients must not be enrolled into the study if, at the time of enrollment, they have any of the following:
  • Presence of active infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.
  • Pregnancy, lactation or unwillingness to use adequate contraceptive methods.
  • Diagnosis of any other inflammatory arthritis or active autoimmune diseases other than RA.
  • Received intra-articular administration of corticosteroids/DMARDs (for other reasons than the current study) within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
  • History or currently active primary or secondary immunodeficiency.
Show all 23Show fewer
  • Concurrent malignancy or history of malignancy (except in situ melanoma) from which the patient has been disease-free for less than 2 years.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  • Treatment with warfarin or other coumarin derivatives.
  • Clinically significant cardiac arrhythmias or requiring permanent medication.
  • Abnormal LVEF or any other abnormalities observed during baseline ECG and echocardiogram investigations that are considered as clinically significant by the investigator; subjects with current or a history of QT/QTc prolongation.
  • Uncontrolled hypertension.
  • Known arterial aneurism at high risk of rupture.
  • Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  • Severe diabetic retinopathy.
  • Major trauma including surgery within 4 weeks prior to administration of study treatment.
  • Known history of allergy or other intolerance to IL10 or other drugs based on human proteins/peptides/antibodies.
  • Treatment with any investigational agent within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
  • Immunization with a live/attenuated vaccine within 4 weeks prior to baseline or plan to receive vaccines during the study.
  • Chronic pain disorders (not RA-related) that might interfere with pain evaluation.
  • Patients requiring stable doses of corticosteroids > 10 mg/day (prednisone equivalent). Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
  • History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.
  • Any condition that in the opinion of the investigator could hamper compliance with the study protocol.

About this study

Official title: A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a. administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for i.a. injections.

Being tested
F8IL10
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • F8IL10Drug

    Also called Dekavil

    The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.

    Patients with arthritis flare(s) in "large joints" (shoulders, elbows, knees and ankles, with the exception of hip) and "small joints" (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per "2010 Rheumatoid Arthritis Classification Criteria" [1] will be treated with increasing dose of F8IL10 according to the schedule detailed below:

    Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10

Study groups in NCT05622175
Study groupRoleWhat they receive
Drug: F8IL10ExperimentalOverall, 32 patients will participate in case no DLT would occur. 1. In the standard 3+3 dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of F8IL10 (from 0.5 to 10 mg) in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 3 patients with escalating doses of F8IL10 until the MAD is reached and won't exceed 10 mg dose level. In case a DLT would be detected, further 3 patients will be enrolled for that cohort in order to confirm the MAD or to proceed with the next dose level. Therefore, up to 30 patients could be enrolled in the dose escalation part. 2. Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level (patients treated at the RD in the course of the dose escalation phase will contribute to the total sample size).
Receives: Drug: F8IL10

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MTD

    Maximum Tolerated Dose (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level.

    Measured: From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

  2. RD

    Recommended Dose (in dose escalation part). The RD is defined by the Data Safety Monitoring Board (DSMB) among the safely tested dose level (i.e. not exceeding the MTD) considering the overall results dataset (e.g. safety, tolerability, efficacy, immunogenicity, pharmacokinetics) obtained in this study.

    Measured: From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

Secondary outcomes (11)

  1. Safety and Tolerability

    Number and frequency of Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) and Drug-Induced Liver Injuries (DILIs)

    Measured: From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

  2. Efficacy measured as improvement in visual analogue scale for involved joint pain (jVAS)

    Preliminary efficay findings using jVAS scale in rheumatoid arthritis for quantifying pain intensity. Patients will assess their own current level of pain related to arthritis in target joint(s) that has been/will be injected. The information refers to a score of the joint pain perceived by the patient over the 7 days prior to the assessment and will be recorded using a 100-mm horizontal VAS where the left end represents "no pain (0%)" and the right end represents "severe pain (100%)". The assessment provided at Day 1 (Week 1) will be considered as baseline measurement.

    Measured: From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

  3. Quality of life - Collection of HAQ-DI for the evaluation of physical function

    Health Assessment Questionnaire-Disability Index (HAQ-DI) as validated tool for the evaluation of Disability Index (DI) or Functional Disability Index (FDI) by considering 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section, the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8. Changes from baseline through treatment period and follow-up will be quantified.

    Measured: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  4. Quality of life - Collection of SF-36 for the evaluation of overall health status

    Short Form Health Survey 36 (SF-36) as validated tool for subject-reported indication of overall health status, including multi-item scales measuring 8 health concepts: (1) physical functioning; (2) role limitations because of physical health problems; (3) bodily pain; (4) social functioning; (5) general mental health; (6) role limitations because of emotional problems; (7) vitality; and (8) general health perceptions. These are summarized in two summary measures of physical and mental health: the Physical Component Summary and Mental Component Summary. Lower scores equate to higher disability and higher scores equate to lower disability. Changes from baseline through treatment period and follow-up will be quantified.

    Measured: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  5. Quality of life - Collection of FACIT-F for the evaluation of self-reported fatigue and its impact upon daily activities and function

    Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) as validated 13-item questionnaire for the assessment of self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). As each of the 13 items of the FACIT-Fatigue scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best. Changes from baseline through treatment period and follow-up will be quantified.

    Measured: At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

  6. Assessment of joint inflammation with ultrasound

    Assessment of improvement of joint synovitis using ultrasound (US) pre-treatment and after the treatment period

    Measured: At day 1 and 57 of treatment period

  7. Assessment of damage with ultrasound

    Assessment of non-progressive bone erosion using ultrasound (US) pre-treatment and after the treatment period

    Measured: At day 1 and 57 of treatment period

  8. Pharmacokinetic (PK) profile F8IL10- Area Under the Curve (AUC)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling.

    Standard PK parameter AUC will be estimated.

    Measured: At day 1 and 29 (F8IL10 administration)

  9. Pharmacokinetic (PK) profile F8IL10- Maximum drug concentration (Cmax)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling.

    Standard PK parameter Cmax will be estimated.

    Measured: At day 1 and 29 (F8IL10 administration)

  10. Pharmacokinetic (PK) profile F8IL10 - Terminal half-life (T½)

    Blood/Synovial fluid samples for PK profile of F8IL10 profile measurements will be collected from all patients enrolled in the study and who receives at least one dose of study drug and have adequate PK sampling.

    Standard PK parameter T½ will be estimated.

    Measured: At day 1 and 29 (F8IL10 administration)

  11. Immunogenicity of F8IL10 (Human Anti-Fusion Antibody formation [HAFA])

    Blood samples to assess the potential development of antibody formation to F8IL10 will be collected during the treatment period and in the first Follow-up

    Measured: At day 1 and 29 (F8IL10 administration) to the first visit of follow up (week 13)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2022
  2. Study start31 Mar 2023 (estimated)
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Why it stopped: Study redesigned and registered under NCT07245992 (Protocol n° PH-F8IL10INTRA-03/24)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Model description
Dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular. A standard 3+3 dose escalation design from 0.5 to 10 mg of F8IL10 until the first instance of a DLT in the observation period from Day 1 to Day 28. In the absence of DLTs, such dose increase will continue until the MAD level is reached and won't exceed 10 mg dose level. With the occurrence of a DLT, the same dose level cohort will be expanded to 6 patients and, if additional DLTs do not occur, the dose escalation will continue to the next dose level. When two DLTs are recorded in the same dose level, MAD is automatically reached. The RD will be then defined by the DSMB .
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05622175
Sponsor's protocol ID
PH-F8IL10INTRA-02/22
Acronym
DekaJoint
Status last verified
Nov 2025
First submitted
3 Nov 2022
Last updated
2 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing F8IL10 in people with Rheumatoid Arthritis, run by Philogen S.p.A..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MTD (time frame: From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05622175.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in